Publications by authors named "Keith Pratz"

64Publications

Azacitidine and Venetoclax in AML. Reply.

N Engl J Med 2020 11;383(21):2088-2089

University of Pennsylvania, Philadelphia, PA.

View Article and Find Full Text PDF
November 2020

Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia.

N Engl J Med 2020 08;383(7):617-629

From the Department of Leukemia, Division of Cancer Medicine, University of Texas M.D. Anderson Cancer Center, Houston (C.D.D., M.K.); the Department of Internal Medicine, Division of Hematology and Oncology, University of California Davis School of Medicine, Sacramento (B.A.J.), the Department of Hematology and Hematopoietic Cell Transplantation and Gehr Family Center for Leukemia Research, City of Hope Comprehensive Cancer Center, Duarte (V. Pullarkat), and Genentech, South San Francisco (W.-J.H.) - all in California; the Section of Hematology and Oncology, Department of Medicine, University of Chicago Medicine, Chicago (M.J.T.), and AbbVie, North Chicago (Y.Z., J.P.) - both in Illinois; the Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston (J.S.G., A.L.); the Australian Centre for Blood Diseases, Alfred Hospital and Monash University, Melbourne, VIC (A.H.W.); the Department of Internal Medicine III, Ulm University Hospital, Ulm, Germany (H.D.); Hôpital St. Louis, Assistance Publique-Hôpitaux de Paris and Université de Paris, Paris (P.F.); the Third Medical Department for Hematology and Oncology, Hanusch Hospital, Vienna (E.K.); the Department of Hematology, Cliniques Universitaires Saint-Luc, Brussels (V.H.); the Department of Medicine, McMaster University, Hamilton, ON, Canada (B.L.); the Department of Hematology, Hospital Clinic, August Pi i Sunyer Biomedical Research Institute, Barcelona (J.E.); the Institute of Hematology and Hospital of Blood Disease, Chinese Academy of Medical Sciences, Peking Union Medical College, Tianjin, China (J.W.); the Department of Hematology, University Hospital Dubrava, University of Zagreb School of Medicine, Zagreb, Croatia (V. Pejsa); the Department of Clinic Subjects, University Hospital Ostrava-Poruba, Ostrava, Czech Republic (R.H.); Helsinki University Hospital Comprehensive Cancer Center, University of Helsinki, Helsinki (K.P.); the Faculty of Medicine, Department of Hematology, University of Debrecen, Debrecen, Hungary (A.I.); Hadassah Medical Center, Jerusalem (D.L.); the Clinic of Hematology, Department of Internal Medicine, University of Genoa, and San Martino Hospital IRCCS - both in Genoa, Italy (R.M.L.); the Department of Hematology and Cell Therapy, Aichi Cancer Center, Nagoya, Japan (K.Y.); the Department of Internal Medicine, Seoul National University College of Medicine (S.-S.Y.), and the Department of Hematology-Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine (J.-H.J.) - both in Seoul, South Korea; the Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan (S.-P.Y.); the Faculty of Medicine, Department of Internal Medicine, Division of Hematology, Ondokuz Mayıs University, Samsun, Turkey (M.T.); and Abramson Cancer Center, University of Pennsylvania, Philadelphia (K.W.P.).

View Article and Find Full Text PDF
August 2020

Sorafenib Dose Recommendation in Acute Myeloid Leukemia Based on Exposure-FLT3 Relationship.

Clin Transl Sci 2018 07 27;11(4):435-443. Epub 2018 Apr 27.

Center for Translational Medicine, University of Maryland Baltimore, Maryland, USA.

View Article and Find Full Text PDF
July 2018

Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia.

Am J Hematol 2018 02 4;93(2):213-221. Epub 2017 Dec 4.

Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center and Weill Cornell Medical College, New York, New York.

View Article and Find Full Text PDF
February 2018

Adaptation to TKI Treatment Reactivates ERK Signaling in Tyrosine Kinase-Driven Leukemias and Other Malignancies.

Cancer Res 2017 10 18;77(20):5554-5563. Epub 2017 Sep 18.

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland.

View Article and Find Full Text PDF
October 2017

Role of Alternative Donor Allogeneic Transplants in the Therapy of Acute Myeloid Leukemia.

J Natl Compr Canc Netw 2017 07;15(7):959-966

Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland.

View Article and Find Full Text PDF
July 2017

Acute myeloid leukemia in the elderly: therapeutic options and choice.

Leuk Lymphoma 2018 02 2;59(2):274-287. Epub 2017 Jun 2.

a Department of Oncology , Johns Hopkins University , Baltimore , MD , USA.

View Article and Find Full Text PDF
February 2018

A Single Center Survey of Health-Related Quality of Life among Acute Myeloid Leukemia Survivors in First Complete Remission.

J Palliat Med 2017 Nov 24;20(11):1267-1273. Epub 2017 May 24.

5 Program in Palliative Medicine and Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins Hospital , Baltimore, Maryland.

View Article and Find Full Text PDF
November 2017

Genomic instability is a principle pathologic feature of FLT3 ITD kinase activity in acute myeloid leukemia leading to clonal evolution and disease progression.

Leuk Lymphoma 2017 09 6;58(9):1-11. Epub 2017 Feb 6.

a Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University , Baltimore , MD , USA.

View Article and Find Full Text PDF
September 2017

How I treat FLT3-mutated AML.

Blood 2017 02 21;129(5):565-571. Epub 2016 Nov 21.

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD.

View Article and Find Full Text PDF
February 2017

Poly (ADP-Ribose) Polymerase Inhibitor Hypersensitivity in Aggressive Myeloproliferative Neoplasms.

Clin Cancer Res 2016 08 15;22(15):3894-902. Epub 2016 Mar 15.

Department of Oncology, Mayo Clinic, Rochester, Minnesota. Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota.

View Article and Find Full Text PDF
August 2016

Two novel germline DDX41 mutations in a family with inherited myelodysplasia/acute myeloid leukemia.

Haematologica 2016 06 4;101(6):e228-31. Epub 2016 Mar 4.

Division of Hematology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA

View Article and Find Full Text PDF
June 2016

A Novel Tandem Duplication Assay to Detect Minimal Residual Disease in FLT3/ITD AML.

Mol Diagn Ther 2015 Dec;19(6):409-17

Division of Molecular Pathology, Department of Pathology, Johns Hopkins University School of Medicine, Park SB202, 600 North Wolfe Street, Baltimore, MD, 21287, USA.

View Article and Find Full Text PDF
December 2015

Improved FLT3 internal tandem duplication PCR assay predicts outcome after allogeneic transplant for acute myeloid leukemia.

Biol Blood Marrow Transplant 2014 Dec 23;20(12):1989-95. Epub 2014 Aug 23.

Department of Pathology, Johns Hopkins University School of Medicine, Baltimore, Maryland; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland. Electronic address:

View Article and Find Full Text PDF
December 2014

Sorafenib is tolerable and improves clinical outcomes in patients with FLT3-ITD acute myeloid leukemia prior to stem cell transplant and after relapse post-transplant.

Am J Hematol 2014 Sep 23;89(9):936-8. Epub 2014 Jun 23.

Department of Internal Medicine, Division of Hematology Oncology, University of Maryland School of Medicine, Marlene and Stewart Greenebaum Cancer Center, Leukemia and Hematologic Malignancies, Baltimore, Maryland.

View Article and Find Full Text PDF
September 2014

Will FLT3 inhibitors fulfill their promise in acute meyloid leukemia?

Curr Opin Hematol 2014 Mar;21(2):72-8

aDepartment of Oncology, Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland bAbramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

View Article and Find Full Text PDF
March 2014

Poly(ADP-ribose) polymerase inhibitor CEP-8983 synergizes with bendamustine in chronic lymphocytic leukemia cells in vitro.

Leuk Res 2014 Mar 30;38(3):411-7. Epub 2013 Dec 30.

Department of Oncology and the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21287, USA. Electronic address:

View Article and Find Full Text PDF
March 2014

HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation.

Biol Blood Marrow Transplant 2014 Mar 1;20(3):314-8. Epub 2013 Dec 1.

The Sidney Kimmel Comprehensive Cancer Center, Department of Oncology at the Johns Hopkins University, Baltimore, Maryland. Electronic address:

View Article and Find Full Text PDF
March 2014

Plasma protein binding of sorafenib, a multi kinase inhibitor: in vitro and in cancer patients.

Invest New Drugs 2012 Dec 17;30(6):2096-102. Epub 2011 Nov 17.

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting-Blaustein Cancer Research Bldg, Room 1M52, Baltimore, MD 21231-1000, USA.

View Article and Find Full Text PDF
December 2012

Quantitation of sorafenib and its active metabolite sorafenib N-oxide in human plasma by liquid chromatography-tandem mass spectrometry.

J Chromatogr B Analyt Technol Biomed Life Sci 2010 Nov 9;878(29):3033-8. Epub 2010 Sep 9.

Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.

View Article and Find Full Text PDF
November 2010

Bench to bedside targeting of FLT3 in acute leukemia.

Curr Drug Targets 2010 Jul;11(7):781-9

Department of Oncology, Division of Hematologic Malignancies, Sidney Kimmel Cancer Center at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21231, USA.

View Article and Find Full Text PDF
July 2010

FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML.

Blood 2010 Feb 10;115(7):1425-32. Epub 2009 Dec 10.

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD 21231, USA.

View Article and Find Full Text PDF
February 2010

A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical response.

Blood 2009 Apr 24;113(17):3938-46. Epub 2008 Nov 24.

Department of Oncology, Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA.

View Article and Find Full Text PDF
April 2009

Incorporating FLT3 inhibitors into acute myeloid leukemia treatment regimens.

Leuk Lymphoma 2008 May;49(5):852-63

Division of Hematologic Malignancies, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA.

View Article and Find Full Text PDF
May 2008

Intestinal lymphangiectasia with protein-losing enteropathy in Waldenstrom macroglobulinemia.

Medicine (Baltimore) 2007 Jul;86(4):210-214

From Department of Medical Oncology (KWP), Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital, Baltimore, Maryland; Division of Hematology (DD, JAL), Department of Internal Medicine; and Department of Laboratory Medicine and Pathology (TCS), Mayo Clinic College of Medicine, Rochester, Minnesota.

View Article and Find Full Text PDF
July 2007

Large cell carcinoma with calcitonin and vasoactive intestinal polypeptide-associated Verner-Morrison syndrome.

Mayo Clin Proc 2005 Jan;80(1):116-20

Department of Internal Medicine, Mayo Clinic College of Medicine, Rochester, Minn 55905, USA.

View Article and Find Full Text PDF
January 2005